Open Nav

Please submit your session questions in advance at

Cox Biosciences LLC

  • Clark Sullivan, Cox Biosciences LLC

Curing Autism and Other Cerebral Folate Deficiencies.

Cox is a phase III pharmaceutical company developing proprietary treatments for autism and other cerebral folate deficiencies. Cox has formulated levoleucovorin into a new liquid dosage format for its most advanced clinical program, and is building off of ground-breaking clinical research from Autism Speaks to move directly into phase III clinical development. The company was founded based on pioneering research at Downstate Medical Center and the discovery of an autoimmune response that inhibits folate transport to the brain in conditions such as autism. Several clinical studies and case reports have demonstrated that high dose reduced folates are capable of overcoming the folate block induced by this immune response, and overcoming language and other neurological deficits in autistic children. Optimum folate therapies are, however, not available to treat children when they are first diagnosed with autism. Cox’s first drug product, LL-One, is a liquid solution of levoleucovorin designed for optimum treatment of autistic children of all ages. The formulation and method of treatment are protected by two granted patents and two pending applications in the United States with corresponding protection around the world.

  • Date:Monday, February 11
  • Time:9:45 AM - 10:00 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23489
  • Goal for Presentation:Make investors and potential partners aware of Cox's development program and opportunity.
  • Company
  • Company HQ City:New York
  • Company HQ State:New York
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:0
  • Year Founded:2017
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Levoleucovorin oral solution
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1
  • Additional Information/Comments:Cox is presently compiling a pre-IND package for submission to FDA later this month. A trial funded by Autism Speaks in 88 children 2.5-5 years of age, using Cox’s drug product, is expected to begin this June (“Clinical Study AS-1”). LL-One is protected by granted patents in the United States, Europe, Japan and Australia, and is also the subject of two pending provisional patent applications in the United States. Cox has not received any third party funding to date for its business and is currently soliciting funds to cover the pre-IND meeting for Clinical Study AS-1, Cox’s oversight and support of AS-1, and to perform preliminary work on the development of complementary drug products for new indications and dosage forms.
Clark Sullivan
Cox Biosciences LLC